Understanding Urinary Incontinence

Urinary incontinence, a condition affecting millions worldwide, is often shrouded in silence and misunderstanding. Far from being a mere inconvenience, it can significantly impact an individual's quality of life, leading to social isolation and emotional distress. This article delves into the various facets of urinary incontinence, shedding light on its prevalence, the different forms it takes, its substantial societal costs, and the evolving landscape of treatment, including the introduction of novel pharmacological solutions.

The Scope of the Problem: More Than Just an Annoyance

The societal burden of urinary incontinence is considerable. In Sweden alone, the estimated annual cost is approximately 2.5 billion Swedish kronor, representing a significant 2% of total healthcare expenditure. A substantial portion of this cost, 1.3 billion kronor in 1995, was attributed to incontinence aids. Beyond the financial implications, incontinence often presents a considerable social handicap for those affected. It is estimated that half a million people in Sweden suffer from urinary incontinence requiring treatment, highlighting the widespread nature of this condition. While often associated with ageing, incontinence can affect individuals of all ages and genders, though it is notably more prevalent in women than men. Factors such as hormonal changes and certain medications, like diuretics used for heart conditions, can contribute to its development.

Understanding the Different Types of Incontinence

Urinary incontinence is not a monolithic condition but rather a spectrum of disorders, broadly categorised into several main types:

1. Urgency Incontinence (Trängningsinkontinens)

This is the most common form, often experienced alongside mixed incontinence. It is characterised by sudden, compelling urges to urinate, often leading to involuntary leakage before reaching a toilet. This is typically caused by overactivity of the bladder muscle (detrusor), leading to unscheduled contractions during the bladder filling phase. In men, urgency incontinence is frequently linked to an enlarged prostate (benign prostatic hyperplasia or BPH), which can irritate the bladder and trigger these involuntary contractions.

2. Stress Incontinence (Ansträngningsinkontinens)

This type of incontinence occurs when physical stress is placed on the bladder. Activities such as coughing, sneezing, laughing, exercising, or lifting heavy objects can cause a sudden increase in abdominal pressure, which then transmits to the bladder. If the pelvic floor muscles and sphincter are weakened, this pressure can overcome their ability to keep the urethra closed, resulting in urine leakage. Stress incontinence is particularly common in women after childbirth or due to menopause.

3. Mixed Incontinence

As the name suggests, this is a combination of both urgency and stress incontinence. Individuals with mixed incontinence experience leakage associated with both sudden urges and physical exertion.

4. Overflow Incontinence

This occurs when the bladder does not empty completely, leading to a constant dribbling of urine. It is often associated with conditions that obstruct urine flow, such as an enlarged prostate in men, or nerve damage that impairs bladder muscle function.

The Male Perspective: Prostate and Incontinence

While urinary incontinence is more common in women, it is a significant issue for men as well. As mentioned, the most frequent cause of incontinence in men is an enlarged prostate. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. As the prostate grows larger, it can press on the urethra, obstructing urine flow and leading to bladder irritation and the symptoms of urgency incontinence. Other causes in men can include prostate surgery, radiation therapy for prostate cancer, or neurological conditions.

Societal Impact and Under-treatment

The pervasive nature of incontinence means it is often a hidden problem. Many individuals suffer in silence due to embarrassment, leading to a significant under-treatment of the condition. Studies indicate that only about a quarter of those experiencing incontinence seek medical help, and among those who do, only 10-20% are prescribed medication. The reliance on incontinence aids, such as absorbent pads and diapers, is high, with approximately 200,000 people in Sweden using some form of aid, which are typically free if prescribed by a healthcare professional.

Treatment Principles: From Aids to Advanced Pharmacology

The management of urinary incontinence has evolved significantly over the years. Historically, the primary approach has been the provision of absorbent products. However, pharmacological interventions have become increasingly important, particularly for urgency incontinence.

Pharmacological Interventions: Anticholinergics

Anticholinergic medications are the cornerstone of pharmacological treatment for urgency incontinence. These drugs work by blocking specific receptors on the bladder muscle cells. These receptors are normally stimulated by a neurotransmitter that causes the bladder muscle to contract. By blocking these receptors, anticholinergics reduce the frequency and intensity of these involuntary contractions, thereby increasing bladder capacity and reducing the urge to urinate. The bladder reflex can be triggered by irritation or reduced inhibition in the nerves controlling bladder and urethral function.

Challenges with Existing Treatments

While effective, older anticholinergic medications, such as oxybutynin, have been associated with significant side effects, most notably dry mouth and constipation. These side effects can be so bothersome that they lead to treatment discontinuation for a substantial proportion of patients, with up to a third of patients stopping oxybutynin due to dry mouth. This highlights the need for treatments with a more favourable side effect profile.

A New Dawn in Incontinence Treatment: Detrusitol

Pharmacia & Upjohn has introduced a new medication, tolterodine, marketed as Detrusitol. This drug has been developed with the primary aim of treating urinary incontinence and received approval from the Swedish Medical Products Agency on September 8th. It is set to be rolled out across Europe and has also seen a registration application filed in the USA. Lars Birgersson, Medical Director of Urology at Pharmacia & Upjohn, expressed considerable optimism, stating, "Pharmacia & Upjohn has high hopes that this can become a very significant product."

Detrusitol's Mechanism and Efficacy

Detrusitol is an anticholinergic agent that has demonstrated a more specific action on the bladder compared to existing medications. Both preclinical experimental studies and clinical trials have shown Detrusitol to be as effective as oxybutynin in inhibiting bladder activity. Studies indicated an increase in bladder capacity by approximately 30% for both medications. Crucially, Detrusitol appears to have a more favourable side effect profile.

Clinical Trials and Patient Experience

A six-month open-label study with Detrusitol revealed that a remarkable 85% of patients chose to continue treatment, suggesting a higher tolerance and satisfaction rate. Furthermore, studies have indicated no adverse interactions with commonly prescribed medications such as diuretics and warfarin, adding to its safety profile. The efficacy and safety of Detrusitol have been rigorously assessed through one of the largest clinical research programmes ever conducted for urinary incontinence, involving a total of 2,600 patients across 15 countries and 8 different studies.

In Sweden, 260 individuals from 30 hospitals participated in the study. Professor Anders Mattiasson from Lund University Hospital, who led the Swedish arm of the research, commented, "Our experiences align with other similar studies. The significant advantage of Detrusitol is the absence of troublesome side effects. With oxybutynin, approximately 30 percent discontinued treatment for that very reason." This reduction in treatment discontinuation due to side effects is a key differentiator for Detrusitol.

Elevating Incontinence as a Health Priority

Urinary incontinence is now recognised as a priority research area for Pharmacia & Upjohn, building on decades of research within its predecessor companies, Kabi and Leo, since the 1970s. There is a growing consensus that incontinence should be treated not as a social stigma but as a recognised medical condition. The upcoming World Health Organization (WHO) conference, the first of its kind, is expected to further contribute to this recognition, aiming to destigmatise and improve the management of incontinence globally. As Anders Mattiasson aptly puts it, "Everyone agrees that incontinence is a hidden problem. It should be recognised as a completely normal illness."

Frequently Asked Questions

Q1: What is the male form of incontinence?
A1: The most common form of incontinence in men is urgency incontinence, often caused by an enlarged prostate which irritates the bladder.

Q2: Is urinary incontinence a common problem?
A2: Yes, urinary incontinence is very common, affecting millions of people. It is estimated that half a million people in Sweden alone require treatment for it.

Q3: What are the main types of urinary incontinence?
A3: The main types are urgency incontinence, stress incontinence, mixed incontinence, and overflow incontinence.

Q4: What are the main side effects of older anticholinergic medications for incontinence?
A4: The most common side effects are dry mouth and constipation.

Q5: What is Detrusitol and how does it work?
A5: Detrusitol (tolterodine) is a newer anticholinergic medication used to treat urgency incontinence. It works by reducing involuntary contractions of the bladder muscle, offering a more specific action and potentially fewer side effects than older treatments.

Q6: How effective is Detrusitol?
A6: Clinical trials show Detrusitol to be as effective as oxybutynin in increasing bladder capacity and reducing incontinence symptoms, with a higher patient retention rate due to a better side effect profile.

Q7: Can incontinence be treated?
A7: Yes, incontinence can be treated through various methods, including lifestyle changes, pelvic floor exercises, medication, and in some cases, surgery. Seeking professional medical advice is the first step.